English

Cardiff Oncology, Inc.

EDGAR

CRDF Current report (8-K) · filed 2026-10-27

Annual consolidated revenue for 2025: about USD 593K, using the latest reported figures. The previous period, 2024, was about USD 683K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

104 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 104000 USD Source

Operating margin

-9,245.19%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -9615000 USD Source
Revenue: 104000 USD Source

Operating cash flow

-11.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24053000 USD Source
Operating Cash Flow: -12288000 USD Source

Cash and cash equivalents: 9.2 million USD 2026-06-30 Source
Exact value

9197000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 68.5 million shares 2026-06-30 Source
Exact value

68502000 shares

Reported share-count change

2.97% · 1.98 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

66526000 shares · 2025-06-30· Source
68502000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

508 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 120000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 593000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 350000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 41000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 104000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-40.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -11258000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -45851000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -38635000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -12345000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -9232000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-40.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -31956000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21122000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -37923000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -31956000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12288000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -24053000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12288000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-27.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-13.2%

Prior period

USD 683,000

2024-01-01 – 2024-12-31
Current period

USD 593,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

593000 − 683000 = -90000 USD

683000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
593000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Year-over-year change in Revenue: -90000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 593000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1097262 Filing: 000119312526067464 Input fundies:Revenue: 683000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1099050 Filing: 000119312526067464
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 420,000

Prior period

−USD 45.43 million

2024-01-01 – 2024-12-31
Current period

−USD 45.85 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-45851000 − -45431000 = -420000 USD

-45431000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-45851000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Year-over-year change in Net income: -420000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -45851000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1430093 Filing: 000119312526067464 Input fundies:NetIncome: -45431000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1431824 Filing: 000119312526067464
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 230,000

Prior period

−USD 37.69 million

2024-01-01 – 2024-12-31
Current period

−USD 37.92 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-37923000 − -37693000 = -230000 USD

-37693000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-37923000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Year-over-year change in Operating cash flow: -230000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -37923000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1474273 Filing: 000119312526067464 Input fundies:OperatingCashFlow: -37693000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1476162 Filing: 000119312526067464
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-45%

Prior period

USD 80,000

2024-01-01 – 2024-12-31
Current period

USD 44,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

44000 − 80000 = -36000 USD

80000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
44000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Year-over-year change in Capital expenditure: -36000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 44000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1483384 Filing: 000119312526067464 Input fundies:CapitalExpenditure: 80000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1485122 Filing: 000119312526067464
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 593,000 100% of revenue
Operating costs Derived USD 49.55 million 8,356% of revenue
Operating income −USD 48.96 million −8,256% of revenue
Tax, interest and other Derived −USD 3.11 million −524% of revenue
Net income −USD 45.85 million −7,732% of revenue

Cash

Operating cash flow −USD 37.92 million −6,395% of revenue
Capital expenditure USD 44,000 7.4% of revenue
Free cash flow Derived −USD 37.97 million −6,403% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 10,635% of revenue.
2017 Operating loss: operating costs were 5,164% of revenue.
2018 Operating loss: operating costs were 4,608% of revenue.
2019 Operating loss: operating costs were 6,918% of revenue.
2020 Operating loss: operating costs were 5,315% of revenue.
2021 Operating loss: operating costs were 8,138% of revenue.
2022 Operating loss: operating costs were 10,437% of revenue.
2023 Operating loss: operating costs were 9,406% of revenue.
2024 Operating loss: operating costs were 7,223% of revenue.
2025 Operating loss: operating costs were 8,356% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	381072	40526683 Derived	-40145611	-941892 Derived	-39203719	-31863338 Derived	Source 2016-01-01 – 2016-12-31: 381072 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -40145611 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -39203719 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -31039855 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 823483 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	505404	26101201 Derived	-25595797	-689053 Derived	-24906744	-23382168 Derived	Source 2017-01-01 – 2017-12-31: 505404 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -25595797 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -24906744 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -23281067 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 101101 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	378325	17431737 Derived	-17053412	-592234 Derived	-16461178	-13204113 Derived	Source 2018-01-01 – 2018-12-31: 378325 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -17053412 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -16461178 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -13199013 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 5100 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	244632	16923126 Derived	-16678494	-264335 Derived	-16414159	-13335122 Derived	Source 2019-01-01 – 2019-12-31: 244632 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -16678494 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -16414159 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -13267500 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 67622 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	366000	19452000 Derived	-19086000	221000 Derived	-19307000	-16526000 Derived	Source 2020-01-01 – 2020-12-31: 366000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -19086000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -19307000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -16315000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 211000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	359000	29214000 Derived	-28855000	-564000 Derived	-28291000	-23245000 Derived	Source 2021-01-01 – 2021-12-31: 359000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -28855000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -28291000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -23040000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 205000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	386000	40288000 Derived	-39902000	-1198000 Derived	-38704000	-34826000 Derived	Source 2022-01-01 – 2022-12-31: 386000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -39902000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -38704000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -33820000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1006000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	488000	45900000 Derived	-45412000	-3971000 Derived	-41441000	-31469000 Derived	Source 2023-01-01 – 2023-12-31: 488000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -45412000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -41441000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -30887000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 582000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	683000	49334000 Derived	-48651000	-3220000 Derived	-45431000	-37773000 Derived	Source 2024-01-01 – 2024-12-31: 683000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -48651000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -45431000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -37693000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 80000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	593000	49553000 Derived	-48960000	-3109000 Derived	-45851000	-37967000 Derived	Source 2025-01-01 – 2025-12-31: 593000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -48960000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -45851000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -37923000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 44000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 593K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	381072	Revenue: 381072 Open source
20172017-12-31	Revenue	505404	Revenue: 505404 Open source
20182018-12-31	Revenue	378325	Revenue: 378325 Open source
20192019-12-31	Revenue	244632	Revenue: 244632 Open source
20202020-12-31	Revenue	366000	Revenue: 366000 Open source
20212021-12-31	Revenue	359000	Revenue: 359000 Open source
20222022-12-31	Revenue	386000	Revenue: 386000 Open source
20232023-12-31	Revenue	488000	Revenue: 488000 Open source
20242024-12-31	Revenue	683000	Revenue: 683000 Open source
20252025-12-31	Revenue	593000	Revenue: 593000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-13.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	21.8%	Revenue: 381072 Open source Revenue: 312812 Open source
20172017-12-31	Year over year	32.6%	Revenue: 505404 Open source Revenue: 381072 Open source
20182018-12-31	Year over year	-25.1%	Revenue: 378325 Open source Revenue: 505404 Open source
20192019-12-31	Year over year	-35.3%	Revenue: 244632 Open source Revenue: 378325 Open source
20202020-12-31	Year over year	49.6%	Revenue: 366000 Open source Revenue: 244632 Open source
20212021-12-31	Year over year	-1.9%	Revenue: 359000 Open source Revenue: 366000 Open source
20222022-12-31	Year over year	7.5%	Revenue: 386000 Open source Revenue: 359000 Open source
20232023-12-31	Year over year	26.4%	Revenue: 488000 Open source Revenue: 386000 Open source
20242024-12-31	Year over year	40%	Revenue: 683000 Open source Revenue: 488000 Open source
20252025-12-31	Year over year	-13.2%	Revenue: 593000 Open source Revenue: 683000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -8,256.3% 2025

Net margin -7,732% 2025

Free cash flow margin -6,402.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-10,534.9%	Operating Income: -40145611 Open source Revenue: 381072 Open source
20172017-12-31	Operating margin	-5,064.4%	Operating Income: -25595797 Open source Revenue: 505404 Open source
20182018-12-31	Operating margin	-4,507.6%	Operating Income: -17053412 Open source Revenue: 378325 Open source
20192019-12-31	Operating margin	-6,817.8%	Operating Income: -16678494 Open source Revenue: 244632 Open source
20202020-12-31	Operating margin	-5,214.8%	Operating Income: -19086000 Open source Revenue: 366000 Open source
20212021-12-31	Operating margin	-8,037.6%	Operating Income: -28855000 Open source Revenue: 359000 Open source
20222022-12-31	Operating margin	-10,337.3%	Operating Income: -39902000 Open source Revenue: 386000 Open source
20232023-12-31	Operating margin	-9,305.7%	Operating Income: -45412000 Open source Revenue: 488000 Open source
20242024-12-31	Operating margin	-7,123.1%	Operating Income: -48651000 Open source Revenue: 683000 Open source
20252025-12-31	Operating margin	-8,256.3%	Operating Income: -48960000 Open source Revenue: 593000 Open source
20162016-12-31	Net margin	-10,287.7%	Net Income: -39203719 Open source Revenue: 381072 Open source
20172017-12-31	Net margin	-4,928.1%	Net Income: -24906744 Open source Revenue: 505404 Open source
20182018-12-31	Net margin	-4,351.1%	Net Income: -16461178 Open source Revenue: 378325 Open source
20192019-12-31	Net margin	-6,709.7%	Net Income: -16414159 Open source Revenue: 244632 Open source
20202020-12-31	Net margin	-5,275.1%	Net Income: -19307000 Open source Revenue: 366000 Open source
20212021-12-31	Net margin	-7,880.5%	Net Income: -28291000 Open source Revenue: 359000 Open source
20222022-12-31	Net margin	-10,026.9%	Net Income: -38704000 Open source Revenue: 386000 Open source
20232023-12-31	Net margin	-8,492%	Net Income: -41441000 Open source Revenue: 488000 Open source
20242024-12-31	Net margin	-6,651.7%	Net Income: -45431000 Open source Revenue: 683000 Open source
20252025-12-31	Net margin	-7,732%	Net Income: -45851000 Open source Revenue: 593000 Open source
20162016-12-31	Free cash flow margin	-8,361.5%	Revenue: 381072 Open source Operating Cash Flow: -31039855 Open source Capital Expenditure: 823483 Open source
20172017-12-31	Free cash flow margin	-4,626.4%	Revenue: 505404 Open source Operating Cash Flow: -23281067 Open source Capital Expenditure: 101101 Open source
20182018-12-31	Free cash flow margin	-3,490.2%	Revenue: 378325 Open source Operating Cash Flow: -13199013 Open source Capital Expenditure: 5100 Open source
20192019-12-31	Free cash flow margin	-5,451.1%	Revenue: 244632 Open source Operating Cash Flow: -13267500 Open source Capital Expenditure: 67622 Open source
20202020-12-31	Free cash flow margin	-4,515.3%	Revenue: 366000 Open source Operating Cash Flow: -16315000 Open source Capital Expenditure: 211000 Open source
20212021-12-31	Free cash flow margin	-6,474.9%	Revenue: 359000 Open source Operating Cash Flow: -23040000 Open source Capital Expenditure: 205000 Open source
20222022-12-31	Free cash flow margin	-9,022.3%	Revenue: 386000 Open source Operating Cash Flow: -33820000 Open source Capital Expenditure: 1006000 Open source
20232023-12-31	Free cash flow margin	-6,448.6%	Revenue: 488000 Open source Operating Cash Flow: -30887000 Open source Capital Expenditure: 582000 Open source
20242024-12-31	Free cash flow margin	-5,530.5%	Revenue: 683000 Open source Operating Cash Flow: -37693000 Open source Capital Expenditure: 80000 Open source
20252025-12-31	Free cash flow margin	-6,402.5%	Revenue: 593000 Open source Operating Cash Flow: -37923000 Open source Capital Expenditure: 44000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -37.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-31039855	Operating Cash Flow: -31039855 Open source
20172017-12-31	Operating cash flow	-23281067	Operating Cash Flow: -23281067 Open source
20182018-12-31	Operating cash flow	-13199013	Operating Cash Flow: -13199013 Open source
20192019-12-31	Operating cash flow	-13267500	Operating Cash Flow: -13267500 Open source
20202020-12-31	Operating cash flow	-16315000	Operating Cash Flow: -16315000 Open source
20212021-12-31	Operating cash flow	-23040000	Operating Cash Flow: -23040000 Open source
20222022-12-31	Operating cash flow	-33820000	Operating Cash Flow: -33820000 Open source
20232023-12-31	Operating cash flow	-30887000	Operating Cash Flow: -30887000 Open source
20242024-12-31	Operating cash flow	-37693000	Operating Cash Flow: -37693000 Open source
20252025-12-31	Operating cash flow	-37923000	Operating Cash Flow: -37923000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -38M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-31863338	Operating Cash Flow: -31039855 Open source Capital Expenditure: 823483 Open source
20172017-12-31	Free cash flow	-23382168	Operating Cash Flow: -23281067 Open source Capital Expenditure: 101101 Open source
20182018-12-31	Free cash flow	-13204113	Operating Cash Flow: -13199013 Open source Capital Expenditure: 5100 Open source
20192019-12-31	Free cash flow	-13335122	Operating Cash Flow: -13267500 Open source Capital Expenditure: 67622 Open source
20202020-12-31	Free cash flow	-16526000	Operating Cash Flow: -16315000 Open source Capital Expenditure: 211000 Open source
20212021-12-31	Free cash flow	-23245000	Operating Cash Flow: -23040000 Open source Capital Expenditure: 205000 Open source
20222022-12-31	Free cash flow	-34826000	Operating Cash Flow: -33820000 Open source Capital Expenditure: 1006000 Open source
20232023-12-31	Free cash flow	-31469000	Operating Cash Flow: -30887000 Open source Capital Expenditure: 582000 Open source
20242024-12-31	Free cash flow	-37773000	Operating Cash Flow: -37693000 Open source Capital Expenditure: 80000 Open source
20252025-12-31	Free cash flow	-37967000	Operating Cash Flow: -37923000 Open source Capital Expenditure: 44000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	55%	Total Liabilities: 24182272 Open source Total Assets: 43950411 Open source
20172017-12-31	Liabilities / assets	47%	Total Liabilities: 5778834 Open source Total Assets: 12284941 Open source
20182018-12-31	Liabilities / assets	28.8%	Total Liabilities: 4088304 Open source Total Assets: 14172496 Open source
20192019-12-31	Liabilities / assets	44.1%	Total Liabilities: 5775202 Open source Total Assets: 13086546 Open source
20202020-12-31	Liabilities / assets	4.9%	Total Liabilities: 6569000 Open source Total Assets: 134727000 Open source
20212021-12-31	Liabilities / assets	6.1%	Total Liabilities: 9127000 Open source Total Assets: 149544000 Open source
20222022-12-31	Liabilities / assets	8.5%	Total Liabilities: 9848000 Open source Total Assets: 116191000 Open source
20232023-12-31	Liabilities / assets	14.6%	Total Liabilities: 11898000 Open source Total Assets: 81637000 Open source
20242024-12-31	Liabilities / assets	14.7%	Total Liabilities: 14241000 Open source Total Assets: 97190000 Open source
20252025-12-31	Liabilities / assets	26.7%	Total Liabilities: 16496000 Open source Total Assets: 61884000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.67× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	5×	Current Assets: 38950192 Open source Current Liabilities: 7797256 Open source
20172017-12-31	Current assets / current liabilities	2.4×	Current Assets: 9468687 Open source Current Liabilities: 3945770 Open source
20182018-12-31	Current assets / current liabilities	4.37×	Current Assets: 12765265 Open source Current Liabilities: 2923318 Open source
20192019-12-31	Current assets / current liabilities	2.37×	Current Assets: 11353729 Open source Current Liabilities: 4781744 Open source
20202020-12-31	Current assets / current liabilities	21.79×	Current Assets: 133356000 Open source Current Liabilities: 6119000 Open source
20212021-12-31	Current assets / current liabilities	22.28×	Current Assets: 146127000 Open source Current Liabilities: 6559000 Open source
20222022-12-31	Current assets / current liabilities	14.25×	Current Assets: 111284000 Open source Current Liabilities: 7808000 Open source
20232023-12-31	Current assets / current liabilities	7.41×	Current Assets: 77412000 Open source Current Liabilities: 10440000 Open source
20242024-12-31	Current assets / current liabilities	7.08×	Current Assets: 95054000 Open source Current Liabilities: 13428000 Open source
20252025-12-31	Current assets / current liabilities	3.67×	Current Assets: 60128000 Open source Current Liabilities: 16394000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 39.2 million Exact value Exact value: -39203719 USD 2016-01-01 – 2016-12-31: -39203719 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2016-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -39203719 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39203719 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828018002226/trov-20171231.xml#247108 Filing: 000162828018002226 The citation records this snapshot. The page link may show a newer release later.	−USD 31.04 million Exact value Exact value: -31039855 USD 2016-01-01 – 2016-12-31: -31039855 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2016-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -31039855 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31039855 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828018002226/trov-20171231.xml#246606 Filing: 000162828018002226 The citation records this snapshot. The page link may show a newer release later.	USD 823,483 Exact value Exact value: 823483 USD 2016-01-01 – 2016-12-31: 823483 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2016-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 823483 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 823483 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828018002226/trov-20171231.xml#262386 Filing: 000162828018002226 The citation records this snapshot. The page link may show a newer release later.	−USD 31.86 million Calculation and evidence -31039855 − 823483 USD Exact free cash flow: -31863338 USD 2016-01-01 – 2016-12-31: -31039855 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 823483 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2016-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -31863338 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31039855 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828018002226/trov-20171231.xml#246606 Filing: 000162828018002226 Input fundies:CapitalExpenditure: 823483 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828018002226/trov-20171231.xml#262386 Filing: 000162828018002226 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 24.91 million Exact value Exact value: -24906744 USD 2017-01-01 – 2017-12-31: -24906744 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2017-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -24906744 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24906744 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-20181231.xml#211672 Filing: 000162828019002546 The citation records this snapshot. The page link may show a newer release later.	−USD 23.28 million Exact value Exact value: -23281067 USD 2017-01-01 – 2017-12-31: -23281067 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2017-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -23281067 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23281067 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-20181231.xml#211170 Filing: 000162828019002546 The citation records this snapshot. The page link may show a newer release later.	USD 101,101 Exact value Exact value: 101101 USD 2017-01-01 – 2017-12-31: 101101 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2017-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 101101 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 101101 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-20181231.xml#223836 Filing: 000162828019002546 The citation records this snapshot. The page link may show a newer release later.	−USD 23.38 million Calculation and evidence -23281067 − 101101 USD Exact free cash flow: -23382168 USD 2017-01-01 – 2017-12-31: -23281067 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 101101 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2017-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -23382168 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23281067 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-20181231.xml#211170 Filing: 000162828019002546 Input fundies:CapitalExpenditure: 101101 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-20181231.xml#223836 Filing: 000162828019002546 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 16.46 million Exact value Exact value: -16461178 USD 2018-01-01 – 2018-12-31: -16461178 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2018-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -16461178 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16461178 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-20191231.xml#241250 Filing: 000162828020002424 The citation records this snapshot. The page link may show a newer release later.	−USD 13.2 million Exact value Exact value: -13199013 USD 2018-01-01 – 2018-12-31: -13199013 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2018-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -13199013 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13199013 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-20191231.xml#240828 Filing: 000162828020002424 The citation records this snapshot. The page link may show a newer release later.	USD 5,100 Exact value Exact value: 5100 USD 2018-01-01 – 2018-12-31: 5100 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2018-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 5100 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5100 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-20191231.xml#253706 Filing: 000162828020002424 The citation records this snapshot. The page link may show a newer release later.	−USD 13.2 million Calculation and evidence -13199013 − 5100 USD Exact free cash flow: -13204113 USD 2018-01-01 – 2018-12-31: -13199013 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5100 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2018-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -13204113 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13199013 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-20191231.xml#240828 Filing: 000162828020002424 Input fundies:CapitalExpenditure: 5100 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-20191231.xml#253706 Filing: 000162828020002424 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 16.41 million Exact value Exact value: -16414159 USD 2019-01-01 – 2019-12-31: -16414159 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2019-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -16414159 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16414159 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/trov-20201231.htm#1122740 Filing: 000162828021003277 The citation records this snapshot. The page link may show a newer release later.	−USD 13.27 million Exact value Exact value: -13267500 USD 2019-01-01 – 2019-12-31: -13267500 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2019-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -13267500 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13267500 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/trov-20201231.htm#1156503 Filing: 000162828021003277 The citation records this snapshot. The page link may show a newer release later.	USD 67,622 Exact value Exact value: 67622 USD 2019-01-01 – 2019-12-31: 67622 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2019-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 67622 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 67622 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/trov-20201231.htm#1160069 Filing: 000162828021003277 The citation records this snapshot. The page link may show a newer release later.	−USD 13.34 million Calculation and evidence -13267500 − 67622 USD Exact free cash flow: -13335122 USD 2019-01-01 – 2019-12-31: -13267500 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 67622 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2019-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -13335122 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13267500 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/trov-20201231.htm#1156503 Filing: 000162828021003277 Input fundies:CapitalExpenditure: 67622 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/trov-20201231.htm#1160069 Filing: 000162828021003277 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 19.31 million Exact value Exact value: -19307000 USD 2020-01-01 – 2020-12-31: -19307000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2020-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -19307000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19307000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm#1084349 Filing: 000162828022003808 The citation records this snapshot. The page link may show a newer release later.	−USD 16.32 million Exact value Exact value: -16315000 USD 2020-01-01 – 2020-12-31: -16315000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2020-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -16315000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16315000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm#1121804 Filing: 000162828022003808 The citation records this snapshot. The page link may show a newer release later.	USD 211,000 Exact value Exact value: 211000 USD 2020-01-01 – 2020-12-31: 211000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2020-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 211000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 211000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm#1125349 Filing: 000162828022003808 The citation records this snapshot. The page link may show a newer release later.	−USD 16.53 million Calculation and evidence -16315000 − 211000 USD Exact free cash flow: -16526000 USD 2020-01-01 – 2020-12-31: -16315000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 211000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2020-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -16526000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16315000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm#1121804 Filing: 000162828022003808 Input fundies:CapitalExpenditure: 211000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm#1125349 Filing: 000162828022003808 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 28.29 million Exact value Exact value: -28291000 USD 2021-01-01 – 2021-12-31: -28291000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2021-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -28291000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28291000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm#1014048 Filing: 000162828023006037 The citation records this snapshot. The page link may show a newer release later.	−USD 23.04 million Exact value Exact value: -23040000 USD 2021-01-01 – 2021-12-31: -23040000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2021-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -23040000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23040000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm#1049481 Filing: 000162828023006037 The citation records this snapshot. The page link may show a newer release later.	USD 205,000 Exact value Exact value: 205000 USD 2021-01-01 – 2021-12-31: 205000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2021-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 205000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 205000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm#1053057 Filing: 000162828023006037 The citation records this snapshot. The page link may show a newer release later.	−USD 23.25 million Calculation and evidence -23040000 − 205000 USD Exact free cash flow: -23245000 USD 2021-01-01 – 2021-12-31: -23040000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 205000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2021-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -23245000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23040000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm#1049481 Filing: 000162828023006037 Input fundies:CapitalExpenditure: 205000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm#1053057 Filing: 000162828023006037 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 38.7 million Exact value Exact value: -38704000 USD 2022-01-01 – 2022-12-31: -38704000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2022-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -38704000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38704000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm#881756 Filing: 000162828024007948 The citation records this snapshot. The page link may show a newer release later.	−USD 33.82 million Exact value Exact value: -33820000 USD 2022-01-01 – 2022-12-31: -33820000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2022-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -33820000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33820000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm#904749 Filing: 000162828024007948 The citation records this snapshot. The page link may show a newer release later.	USD 1.01 million Exact value Exact value: 1006000 USD 2022-01-01 – 2022-12-31: 1006000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2022-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 1006000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1006000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm#907466 Filing: 000162828024007948 The citation records this snapshot. The page link may show a newer release later.	−USD 34.83 million Calculation and evidence -33820000 − 1006000 USD Exact free cash flow: -34826000 USD 2022-01-01 – 2022-12-31: -33820000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1006000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2022-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -34826000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33820000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm#904749 Filing: 000162828024007948 Input fundies:CapitalExpenditure: 1006000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm#907466 Filing: 000162828024007948 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 41.44 million Exact value Exact value: -41441000 USD 2023-01-01 – 2023-12-31: -41441000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2023-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -41441000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41441000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm#1280114 Filing: 000095017025028992 The citation records this snapshot. The page link may show a newer release later.	−USD 30.89 million Exact value Exact value: -30887000 USD 2023-01-01 – 2023-12-31: -30887000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2023-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -30887000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30887000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm#1318740 Filing: 000095017025028992 The citation records this snapshot. The page link may show a newer release later.	USD 582,000 Exact value Exact value: 582000 USD 2023-01-01 – 2023-12-31: 582000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2023-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 582000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 582000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm#1326499 Filing: 000095017025028992 The citation records this snapshot. The page link may show a newer release later.	−USD 31.47 million Calculation and evidence -30887000 − 582000 USD Exact free cash flow: -31469000 USD 2023-01-01 – 2023-12-31: -30887000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 582000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2023-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -31469000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30887000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm#1318740 Filing: 000095017025028992 Input fundies:CapitalExpenditure: 582000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm#1326499 Filing: 000095017025028992 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 45.43 million Exact value Exact value: -45431000 USD 2024-01-01 – 2024-12-31: -45431000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2024-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -45431000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45431000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1431824 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	−USD 37.69 million Exact value Exact value: -37693000 USD 2024-01-01 – 2024-12-31: -37693000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2024-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -37693000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37693000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1476162 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	USD 80,000 Exact value Exact value: 80000 USD 2024-01-01 – 2024-12-31: 80000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2024-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 80000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 80000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1485122 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	−USD 37.77 million Calculation and evidence -37693000 − 80000 USD Exact free cash flow: -37773000 USD 2024-01-01 – 2024-12-31: -37693000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 80000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2024-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -37773000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37693000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1476162 Filing: 000119312526067464 Input fundies:CapitalExpenditure: 80000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1485122 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 45.85 million Exact value Exact value: -45851000 USD 2025-01-01 – 2025-12-31: -45851000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Net Income: -45851000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45851000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1430093 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	−USD 37.92 million Exact value Exact value: -37923000 USD 2025-01-01 – 2025-12-31: -37923000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Operating Cash Flow: -37923000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37923000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1474273 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	USD 44,000 Exact value Exact value: 44000 USD 2025-01-01 – 2025-12-31: 44000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Capital Expenditure: 44000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1483384 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.	−USD 37.97 million Calculation and evidence -37923000 − 44000 USD Exact free cash flow: -37967000 USD 2025-01-01 – 2025-12-31: -37923000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 44000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cardiff Oncology, Inc. · 2025-12-31 Cardiff Oncology, Inc. (edgar:1213037) Free cash flow: -37967000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:13:02Z Snapshot: 02fbfeb7c0a43418ac0549f7d95ddbf8906e259c86925842088ae89cadc0061a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1213037?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37923000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1474273 Filing: 000119312526067464 Input fundies:CapitalExpenditure: 44000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm#1483384 Filing: 000119312526067464 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

112 filings · 4,602 latest values · 4,602 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001213037, 1213037, CRDF, edgar:1213037

Also known as CARDIFF ONCOLOGY, INC., CARDIFF ONCOLOGY, INC., Cardiff Oncology, Inc., Cardiff Oncology, Inc., TrovaGene Inc., Trovagene, Inc., USED KAR PARTS INC, XENOMICS INC

Cardiff Oncology, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation